Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)
Vertex Pharmaceuticals' quarterly Income from Continuing Operations came in at 1031400000.0 in Q1 2026, up 59.59% year-on-year from 646300000.0 in Q1 2025, and down 13.41% quarter-over-quarter from 1191100000.0 in Q4 2025.
Vertex Pharmaceuticals has reported Income from Continuing Operations for 18 years, with the latest figure at 1031400000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 59.59% year-over-year to 1031400000.0; the trailing twelve-month figure through Mar 2026 stood at 4338300000.0 (up 538.7% YoY), and the FY2025 full-year result was 3953200000.0, up 838.09% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1031400000.0, down from 1191100000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1191100000.0 in Q4 2025, with the low at 3593600000.0 in Q2 2024.
- Average Income from Continuing Operations over 5 years is 670035294.12, with a median of 930500000.0 recorded in 2022.
- Year-over-year, Income from Continuing Operations soared 1109.7% in 2022 and tumbled 492.44% in 2024.
- Tracing VRTX's Income from Continuing Operations over 5 years: stood at 818900000.0 in 2022, then rose by 18.31% to 968800000.0 in 2023, then slipped by 5.76% to 913000000.0 in 2024, then surged by 30.46% to 1191100000.0 in 2025, then slipped by 13.41% to 1031400000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1031400000.0 (Q1 2026), 1191100000.0 (Q4 2025), and 1082900000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.19 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 646.30 Mn |
| Dec 31, 2024 | 913.00 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | -3.59 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 968.80 Mn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 915.70 Mn |
| Mar 31, 2023 | 699.80 Mn |
| Dec 31, 2022 | 818.90 Mn |
| Sep 30, 2022 | 930.50 Mn |
| Jun 30, 2022 | 810.50 Mn |
| Mar 31, 2022 | 762.10 Mn |
| Dec 31, 2021 | 770.10 Mn |
| Sep 30, 2021 | 851.90 Mn |
| Jun 30, 2021 | 67.00 Mn |
| Mar 31, 2021 | 653.10 Mn |
| Dec 31, 2020 | 604.19 Mn |
| Sep 30, 2020 | 667.43 Mn |
| Jun 30, 2020 | 837.27 Mn |
| Mar 31, 2020 | 602.75 Mn |
| Dec 31, 2019 | 583.23 Mn |
| Sep 30, 2019 | 57.52 Mn |
| Jun 30, 2019 | 267.43 Mn |
| Mar 31, 2019 | 268.63 Mn |
| Dec 31, 2018 | 1.53 Bn |
| Sep 30, 2018 | 128.46 Mn |
| Jun 30, 2018 | 206.25 Mn |
| Mar 31, 2018 | 227.30 Mn |
| Dec 31, 2017 | 102.19 Mn |
| Sep 30, 2017 | -290.97 Mn |
| Jun 30, 2017 | 31.17 Mn |
| Mar 31, 2017 | 249.55 Mn |
| Dec 31, 2016 | 27.76 Mn |
| Sep 30, 2016 | -39.54 Mn |
| Jun 30, 2016 | -36.15 Mn |
| Mar 31, 2016 | -36.10 Mn |
| Dec 31, 2015 | -74.67 Mn |
| Sep 30, 2015 | -93.82 Mn |
| Jun 30, 2015 | -220.99 Mn |
| Mar 31, 2015 | -198.70 Mn |
| Dec 31, 2014 | -180.64 Mn |
| Sep 30, 2014 | -170.00 Mn |
| Jun 30, 2014 | -159.09 Mn |
| Mar 31, 2014 | -232.11 Mn |
| Dec 31, 2013 | -20.92 Mn |
| Sep 30, 2013 | -121.46 Mn |
| Jun 30, 2013 | -54.35 Mn |
| Mar 31, 2013 | -306.90 Mn |
| Dec 31, 2012 | -78.08 Mn |
| Sep 30, 2012 | -26.47 Mn |
| Jun 30, 2012 | -34.47 Mn |
| Mar 31, 2012 | 87.88 Mn |
| Dec 31, 2011 | 188.14 Mn |
| Sep 30, 2011 | 228.45 Mn |
| Mar 31, 2011 | -176.10 Mn |
| Dec 31, 2010 | -180.39 Mn |
| Sep 30, 2010 | -208.96 Mn |
| Jun 30, 2010 | -200.01 Mn |
| Mar 31, 2010 | -163.78 Mn |
| Dec 31, 2009 | -150.95 Mn |
| Sep 30, 2009 | -149.57 Mn |
| Jun 30, 2009 | -159.00 Mn |
| Mar 31, 2009 | -162.67 Mn |